Next 10 |
2023-04-12 19:19:39 ET PLx Pharma ( NASDAQ: PLXP ) on Wednesday said it intended to file for bankruptcy and had entered into a stalking horse asset purchase deal to sell its drug-delivery platform and brand of aspirin capsules. Shares of the micro-cap company rose 9.2% to ...
SPARTA, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ and VAZALORE ® ,...
2023-04-11 16:52:31 ET PLx Pharma ( NASDAQ: PLXP ) was notified by the Listing Qualifications Department to delist the Co.’s securities from Nasdaq , citing that for a period of 30 consecutive business days, the bid price of its common stock had closed below the mi...
SPARTA, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to...
2023-04-11 06:00:00 ET 3 Tips for Finding Winning Penny Stocks in 2023 The potential for exponential growth has made penny stocks a favorite among investors seeking to capitalize on undervalued, up-and-coming companies. Penny stocks , typically defined as those trading below $5 per ...
PLx Pharma Inc. (PLXP) Q3 2022 Earnings Conference Call November 11, 2022 8:30 am ET Company Participants Natasha Giordano - President, Chief Executive Officer Rita O’Connor - Chief Financial Officer Asif Ali - Preventative Cardiologist Janet Barth - V...
PLx Pharma press release ( NASDAQ: PLXP ): Q3 GAAP EPS of -$0.30. Revenue of $0.39M (-94.1% Y/Y). For further details see: PLx Pharma GAAP EPS of -$0.30, revenue of $0.39M
PLx Pharma press release ( NASDAQ: PLXP ): Q3 Non-GAAP EPS of -$0.37. Revenue of $0.39M (-94.1% Y/Y). As of September 30, 2022, the Company had $25.8 million in cash and cash equivalents, approximately $0.1 million in accounts receivable and zero debt on its balance ...
- Significant Reduction in Operating Expenses - Strategic Alternatives Process Ongoing Total Net Sales of $0.4 Million, Including $0.3 Million of Unfavorable Adjustments for Additional Trade Allowances and Incremental Sales Returns Reserves in Q3 2022 Total Ope...
SPARTA, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the pot...
News, Short Squeeze, Breakout and More Instantly...
SPARTA, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ and VAZALORE ® ,...
SPARTA, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to...
2023-04-11 06:00:00 ET 3 Tips for Finding Winning Penny Stocks in 2023 The potential for exponential growth has made penny stocks a favorite among investors seeking to capitalize on undervalued, up-and-coming companies. Penny stocks , typically defined as those trading below $5 per ...